St. Jude Children's Research Hospital structural biologists have deciphered how the structure of the enzyme called Abl regulates its activity, enabling the enzyme to switch itself on and off. Understanding Abl's regulation ...
Sep 26, 2017
0
26
Two drugs, already approved for safe use in people, may be able to improve therapy for chronic myeloid leukemia (CML), a blood cancer that affects myeloid cells, according to results from a University of Iowa study in mice.
Sep 25, 2017
0
58
Mouse models have advanced our understanding of immune function and disease in many ways but they have failed to account for the natural diversity in human immune responses. As a result, insights gained in the lab may be ...
Jul 26, 2017
0
22
Adding an investigational antibody to the chemotherapy rituximab appears to restore its cancer-killing properties in certain leukemia patients with a natural resistance to the drug, according to a small, proof-of-concept ...
Jun 28, 2017
0
4
Researchers have uncovered how mutations in a protein network drive several high-risk leukemias, offering new prospects for novel therapies. An existing drug might be repurposed to treat these leukemias, and the new understanding ...
Jun 14, 2017
0
0
In 2002, the FDA approved the drug imatinib as a first-line therapy for adults with chronic myeloid leukemia (CML) caused by the fusion gene BCR-ABL, known as the Philadelphia chromosome. The approval dramatically extended ...
Jun 5, 2017
0
1
Physicians paid by pharmaceutical companies for meals, talks and travel had higher odds of prescribing those companies' drugs to treat two cancer types, a University of North Carolina Lineberger Comprehensive Cancer Center-led ...
Jun 1, 2017
0
1
Combining the kinase inhibitor ibrutinib with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to new ...
May 31, 2017
0
0
University of Georgia researchers, with colleagues from the University of Tokyo, have identified a new drug target for the two most common types of myeloid leukemia, including a way to turn back the most aggressive form of ...
May 17, 2017
0
79
Cells exposed to stressful situations respond with precise defense mechanisms programmed in their genes. In breast cancer, these defenses are altered so that they are always on, but how that happens is unknown. Florida Institute ...
May 3, 2017
0
1
